ESMO abstracts are available

The following are the abstracts I was able to find. I suspect there are more.

RXDX abstract – 19 patients tested at different dose levels, 7 responded


Japanese trial, 28 pretreated with Crizotinib. Response rate was 58.3%

Two novel mutations found to Alectinib.


Abstract 1295P

Abstract 1293P


As of 17 March 2014, 125 pts were enrolled: 66 in Phase 1 and 59 in Phase 2. Among 51 evaluable ALK+ patients with prior crizotinib, 69% responded.


This entry was posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, brigatinib-Alunbrig from Takeda, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, RXDX-101 - entrectinib - by Ignyta. Bookmark the permalink.

Leave a Reply